Related Experiment Video

Updated: Aug 1, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity

Chidambaram Ramachandran1, Brian P Kennedy

  • 1Department of Biochemistry and Molecular Biology, Merck Frosst Canada & Co, Pointe-Claire, Quebec, Canada. chidambaram_ramachandran@merck.com

Current Topics in Medicinal Chemistry
|April 8, 2003
PubMed

Insights

Protein tyrosine phosphatase 1B (PTP1B) deficiency in mice improves insulin sensitivity and glucose homeostasis. These mice are also resistant to diet-induced obesity, highlighting PTP1B as a therapeutic target for type 2 diabetes.

Area of Science:

  • Biochemistry
  • Metabolic Disease Research
  • Molecular Endocrinology

Background:

  • Insulin receptor autophosphorylation is key to insulin signal transduction.
  • Identifying tyrosine phosphatases regulating insulin receptor dephosphorylation is crucial.
  • Protein tyrosine phosphatase 1B (PTP1B) is a potential regulator of insulin action.

Purpose of the Study:

  • To investigate the role of PTP1B in insulin signaling and glucose homeostasis.
  • To evaluate PTP1B as a therapeutic target for type 2 diabetes and obesity.

Main Methods:

  • Phenotypic analysis of PTP1B deficient mice.
  • Assessment of insulin sensitivity and glucose homeostasis.
  • Measurement of insulin receptor phosphorylation in liver and muscle.

Main Results:

  • PTP1B deficient mice exhibit enhanced insulin sensitivity and maintain glucose homeostasis with lower insulin levels.
  • Increased insulin receptor phosphorylation observed in PTP1B deficient mice post-insulin administration.
  • PTP1B deficient mice demonstrated resistance to diet-induced obesity.

Conclusions:

  • PTP1B acts as a negative regulator of insulin action.
  • PTP1B is a promising therapeutic target for type 2 diabetes and obesity intervention.

More Related Videos

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.